NCT07219030PHASE1RecruitingAccepts Healthy Volunteers
A Study to Assess the Adverse Events and How Oral Emraclidine Moves Through the Body of Healthy Elderly Adult Participants
AbbVie
Start Date
10/8/2025
Completion Date
3/1/2027
Summary
This study is to assess how oral emraclidine moves through the body of healthy elderly adult participants, and assess adverse events, and tolerability.
Eligibility Criteria
Age Range: 65 years to 85 years
Inclusion Criteria:
* BMI is ≥ 18.0 to ≤ 32.0 kg/m2 after rounding to the tenths decimal at Screening. BMI is calculated as weight in kg divided by the square of height measured in meters.
* Body weight \> 45 kg at the time of screening and upon initial confinement.
* A condition of general good health, based upon the results of a medical history, physical examination, vital signs, laboratory profile and a 12-lead ECG.
Exclusion Criteria:
* History of any clinically significant cardiac, respiratory (except mild asthma as a child), renal, hepatic, gastrointestinal, genitourinary, immunological, hematologic, neurological or psychiatric disease or disorder, or any other uncontrolled medical illness.
* History of any clinically significant sensitivity or allergy to any medication or food.
* Evidence of dysplasia or history of malignancy (including lymphoma and leukemia) other than successfully treated non-metastatic cutaneous squamous cell, basal cell carcinoma or localized carcinoma in situ of the cervix.
Interventions
DRUG
Emraclidine
DRUG
Placebo
Conditions
Healthy Volunteer
Locations
Altasciences Clinical Los Angeles /ID# 276854
Cypress, California 90630
United States
K2 Medical Research, LLC /ID# 276636
Maitland, Florida 32751
United States
Clinical Pharmacology Of Miami /ID# 276856
Miami, Florida 33172
United States
Acpru /Id# 276996
Grayslake, Illinois 60030
United States